ArticleThe journal of allergy and clinical immunology. Global2025
Phase 1 study of safety, tolerability, and efficacy of intradermal DNA vaccine ASP2390 in adults allergic to house dust mites.
Thomas Kayser et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.